Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00572559 · ClinicalTrials.gov registry record · Phase 4

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus

A Phase 4 study of Pneumonia, Ventilator-Associated, sponsored by Pfizer.

Completed
Registry status
Phase 4
Development phase
149
Enrollment target
20
Study locations

NCT00572559 is a Phase 4 study of Pneumonia, Ventilator-Associated that has completed, run by Pfizer. The registered enrollment target is 149 participants. The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00572559, a Phase 4 study of Pneumonia, Ventilator-Associated, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 4
Development phase
149 participants
Enrollment target
20
Study locations

Study Summary

Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly leads to prolonged mechanical ventilation and is probably associated with higher mortality. The purpose of this protocol is to directly compare linezolid and vancomycin specifically for MRSA VAP.

Interventions

  • DRUG Vancomycin
  • DRUG Linezolid

Study Locations (20)

California

  • Pfizer Investigational Site - Palm Springs
  • Pfizer Investigational Site - Rancho Mirage
  • Pfizer Investigational Site - Redlands
  • Pfizer Investigational Site - Sacramento
  • Pfizer Investigational Site - Sacramento

Georgia

  • Pfizer Investigational Site - Augusta
  • Pfizer Investigational Site - Decatur
  • Pfizer Investigational Site - North East Atlanta
  • Pfizer Investigational Site - North East Atlanta
  • Pfizer Investigational Site - North East Atlanta

Illinois

  • Pfizer Investigational Site - Chicago
  • Pfizer Investigational Site - Peoria
  • Pfizer Investigational Site - Peoria
  • Pfizer Investigational Site - Peoria

Connecticut

  • Pfizer Investigational Site - Norwalk
  • Pfizer Investigational Site - Waterbury
  • Pfizer Investigational Site - Waterbury

Arizona

  • Pfizer Investigational Site - Phoenix
  • Pfizer Investigational Site - Phoenix

Hawaii

  • Pfizer Investigational Site - ‘Ewa Beach

Trial Details

FieldValue
Enrollment Target 149 participants
Start Date 2002-11
Est. Completion 2005-01
Phase Phase 4

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT00572559

The ClinicalTrials.gov registry entry for NCT00572559 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Pneumonia, Ventilator-Associated appearing as the primary indexed condition, and to 2 interventions - of which Vancomycin is the first listed.

NCT00572559 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT00572559 about?

NCT00572559 is a clinical study titled "Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus". Ventilator-associated pneumonia (VAP) is a commonplace complication of intensive care patients ventilated for longer than 48 hours. Methicillin-resistant Staphylococcus aureus (MRSA) is the cause of late onset VAP in up to about 30% of cases in US hospitals. Ineffective treatment of MRSA VAP clearly...

What is the current status of trial NCT00572559?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 149 participants. The study started on 2002-11. Estimated completion is 2005-01.

What conditions does trial NCT00572559 study?

This clinical trial studies the following conditions: Pneumonia, Ventilator-Associated.

What interventions are being tested in trial NCT00572559?

The interventions under investigation include: Vancomycin (DRUG), Linezolid (DRUG).

Who is sponsoring clinical trial NCT00572559?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00572559 being conducted?

This trial has 20 study locations across Arizona, California, Connecticut, Georgia, Hawaii. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pneumonia, Ventilator-Associated

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.